UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation

Blood cancer journal (New York), 2022-01, Vol.12 (1), p.13-13, Article 13

2022

Volltextzugriff (PDF)

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies

PloS one, 2018-06, Vol.13 (6), p.e0199108-e0199108

2018

Volltextzugriff (PDF)

ALK-activating homologous mutations in LTK induce cellular transformation

PloS one, 2012-02, Vol.7 (2), p.e31733

2012

Volltextzugriff (PDF)

CRLF2 and JAK2 in B-Progenitor Acute Lymphoblastic Leukemia: A Novel Association in Oncogenesis

Cancer research (Chicago, Ill.), 2010-10, Vol.70 (19), p.7347-7352

2010

Volltextzugriff (PDF)

Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms

Frontiers in immunology, 2020-11, Vol.11, p.604142-604142

2020

Volltextzugriff (PDF)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis

Cancers, 2020-08, Vol.12 (8), p.2278

2020

Volltextzugriff (PDF)

The Ras branch of small Gtpases: Ras family members don’t fall far from the tree

Current Opinion in Cell Biology, 2000-04, Vol.12 (2), p.157-165

2000

Volltextzugriff (PDF)

Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism

Nature cell biology, 2002-08, Vol.4 (8), p.621-625

2002

Volltextzugriff (PDF)

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN

Blood advances, 2019-11, Vol.3 (22), p.3503-3514

2019

Volltextzugriff (PDF)

Regulation of MDMX Expression by Mitogenic Signaling

Molecular and Cellular Biology, 2008-03, Vol.28 (6), p.1999-2010

2008

Volltextzugriff (PDF)

Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor

Proceedings of the National Academy of Sciences - PNAS, 2007-11, Vol.104 (47), p.18502-18507

2007

Volltextzugriff (PDF)

Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway

Cancer biology & therapy, 2010-11, Vol.10 (10), p.979-982

2010

Volltextzugriff (PDF)

Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors

The Journal of biological chemistry, 2010-05, Vol.285 (22), p.16651-16663

2010

Volltextzugriff (PDF)

Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof

Journal of medicinal chemistry, 2021-02, Vol.64 (4), p.2228-2241

2021

Volltextzugriff (PDF)

Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity

Biochemical journal, 2011-08, Vol.438 (1), p.155-164

2011

Volltextzugriff (PDF)

Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ

Biochemical journal, 2010-12, Vol.432 (2), p.255-265

2010

Volltextzugriff (PDF)

JAK2 activation in myeloproliferative neoplasms: A potential role for heterodimeric receptors

Cell cycle (Georgetown, Tex.), 2008-03, Vol.7 (6), p.714-719

Reuther, Gary W.

2008

Volltextzugriff (PDF)

Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model

FEBS open bio, 2019-10, Vol.9 (10), p.1689-1704

2019

Volltextzugriff (PDF)

Involvement of Fibroblast Growth Factor Receptor 2 Isoform Switching in Mammary Oncogenesis

Molecular cancer research, 2008-03, Vol.6 (3), p.435-445

2008

Volltextzugriff (PDF)

Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics

Molecular cancer therapeutics, 2017-06, Vol.16 (6), p.1054-1067

2017

Volltextzugriff (PDF)

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms

American journal of hematology, 2024-06, Vol.99 (6), p.1040-1055

2024

Volltextzugriff (PDF)

Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator Approach

Proteomics (Weinheim), 2020-12, Vol.20 (24), p.e2000116-n/a

2020

Volltextzugriff (PDF)

Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

Clinical cancer research, 2023-08, Vol.29 (15), p.2919-2932

2023

Volltextzugriff (PDF)

RasGRP4 Is a Novel Ras Activator Isolated from Acute Myeloid Leukemia

The Journal of biological chemistry, 2002-08, Vol.277 (34), p.30508-30514

2002

Volltextzugriff (PDF)

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells

Oncotarget, 2015-11, Vol.6 (37), p.40141-40157

2015

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(74)

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Life Sciences & Biomedicine
(40)
Humans
(39)
Animals
(23)
Mice
(17)
Biochemistry & Molecular Biology
(12)
Oncology
(12)
Signal Transduction
(12)
Cell Biology
(11)
Cell Line, Tumor
(11)
Protein Kinase Inhibitors - Pharmacology
(11)
Proteins
(10)
Cell Line
(9)
Mutation
(9)
Tumors
(9)
Janus Kinase 2 - Metabolism
(8)
Kinases
(8)
Janus Kinase 2 - Genetics
(7)
Biological And Medical Sciences
(6)
Cancer
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies

ALK-activating homologous mutations in LTK induce cellular transformation

CRLF2 and JAK2 in B-Progenitor Acute Lymphoblastic Leukemia: A Novel Association in Oncogenesis

Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis

The Ras branch of small Gtpases: Ras family members don’t fall far from the tree

Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN

Regulation of MDMX Expression by Mitogenic Signaling

Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor

Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway

Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors

Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof

Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity

Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ

JAK2 activation in myeloproliferative neoplasms: A potential role for heterodimeric receptors

Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model

Involvement of Fibroblast Growth Factor Receptor 2 Isoform Switching in Mammary Oncogenesis

Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms

Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator Approach

Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

RasGRP4 Is a Novel Ras Activator Isolated from Acute Myeloid Leukemia

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells

Suchergebnisse filtern